Cyramza (ramucirumab; Eli Lilly) Drug Overview 2019

Figure 1: The author's drug assessment summary of Cyramza for HCC
Figure 2: The author's drug assessment summary of Cyramza for HCC
Figure 3: Cyramza sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 4: Cyramza for non-small cell lung cancer – SWOT analysis
Figure 5: The author's drug assessment summary for Cyramza in non-small cell lung cancer
Figure 6: The author's drug assessment summary for Cyramza in non-small cell lung cancer
Figure 7: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Cyramza for gastric cancer – SWOT analysis
Figure 9: The author's drug assessment summary of Cyramza for gastric cancer
Figure 10: The author's drug assessment summary of Cyramza for gastric cancer
Figure 11: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Cyramza for colorectal cancer – SWOT analysis
Figure 13: The author's drug assessment summary of Cyramza for colorectal cancer
Figure 14: The author's drug assessment summary of Cyramza for colorectal cancer
Figure 15: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Cyramza for urothelial bladder cancer – SWOT analysis
Figure 17: The author's drug assessment summary for Cyramza in urothelial bladder cancer
Figure 18: The author's drug assessment summary for Cyramza in urothelial bladder cancer

Table 1: Recent high-impact events for Cyramza in HCC
Table 2: Cyramza drug profile
Table 3: Approval history of Cyramza for HCC in the US, Japan, and five major EU markets
Table 4: Trials of Cyramza for HCC
Table 5: Cyramza for HCC – SWOT analysis
Table 6: Cyramza drug profile
Table 7: Cyramza pivotal trial data in non-small cell lung cancer
Table 8: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
Table 9: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Cyramza patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 11: Cyramza drug profile
Table 12: Cyramza pivotal trial data in gastric cancer
Table 13: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 14: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Table 15: Cyramza drug profile
Table 16: Cyramza Phase III data in colorectal cancer
Table 17: Cyramza Phase I trials in colorectal cancer
Table 18: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 19: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
Table 20: Cyramza drug profile
Table 21: Cyramza Phase III trial in urothelial bladder cancer
Table 22: Cyramza early-phase data in urothelial bladder cancer